2型糖尿病轻度认知功能障碍患者应用阿格列汀治疗的有效性及安全性

doi:10.3969/j.issn.10073205.2019.01.009

河北医科大学学报

2型糖尿病轻度认知功能障碍患者应用阿格列汀治疗的有效性及安全性

1.石家庄信息工程职业学院校医院，河北石家庄 050035；2.河北医科大学第一医院内分泌科，河北石家庄 050031

出版日期:2019-12-25 发布日期:2018-12-29
作者简介:王静(1976-)，女，河北衡水人，石家庄信息工程职业学院主管护师，从事临床护理学研究。
基金资助:
河北省科技计划项目（16277789D）；河北省医学科学研究重点课题（20170506）

Efficacy and safety of alogliptin for patients with type 2 diabetic mild cognitive impairment#br#

1.The School Hospital, Shijiazhuang Information Engineering Vocational College, Hebei Province, Shijiazhuang 050035, China;
2.Department of Endocrinology, the First Hospital of Hebei Medical University, Shijiazhuang 050031, China

Online:2019-12-25 Published:2018-12-29

摘要/Abstract

摘要： ［摘要］〓
〖HTH〗目的〖HTSS〗〖KG*2〗探讨2型糖尿病轻度认知功能障碍（mild cognitive impairment，MCI）患者在二甲双胍基础上加用胰岛素促泌剂、α糖苷酶抑制剂、二肽基肽酶(dipeptidyl peptidase4，DPP4)抑制剂治疗有效性、安全性的区别。
〖HTH〗方法〖HTSS〗〖KG*2〗将2型糖尿病MCI患者120例随机分为阿格列汀组、阿卡波糖组和瑞格列奈组各40例。阿格列汀组加用阿格列汀，阿卡波糖组加用阿卡波糖，瑞格列奈组加用瑞格列奈。疗程24周。测定糖化血红蛋白（hemoglobin A1c，HbA1c）、空腹血糖（fasting plasma glucose，FPG）、餐后2 h血糖（2 h postprandial blod glucose,2 hPBG）、总胆固醇(total cholesterol，TC)、三酰甘油(triglycerides，TG)，记录所有低血糖事件、胃肠道反应及HbA1c达标率。
〖HTH〗结果〖HTSS〗〖KG*2〗与治疗前比较，3组HbA1c、FPG、2 hPBG均显著下降（P＜001），TG、TC无显著变化（P＞005）。同一时间点各组间HbA1c、FPG、2 hPBG、TG和TC差异均无统计学意义（P＞005）。治疗结束时，阿格列汀组血糖达标率最高74.36%（χ2=6.496，P＜001），胃肠道反应发生率最低0.00%(χ2=37.853，P＜001)，低血糖发生率最低2.56%（χ2=16.955，P＜001）。
〖HTH〗结论〖HTSS〗〖KG*2〗阿格列汀治疗2型糖尿病MCI患者，降糖效果不劣于阿卡波糖和瑞格列奈，低血糖发生率、胃肠道反应发生率更低。

关键词: 糖尿病, 2型, 轻度认知障碍, 阿格列汀

Abstract: ［Abstract］ Objective〖HTSS〗〓To explore the efficacy and safety of alogliptin, acarbose and repaglinide in patients with type 2 diabetic mild cognitive impairment inadequately controlled by metformin.
〖HTH〗〖WTHZ〗Methods〖HTSS〗〓The 120 patients with type 2 diabetic mild cognitive impairment inadequately controlled by metformin were randomly divided into thealogliptin group(n=40), theacarbose group(n=40) and therepaglinidegroup(n=40). During the 22week treatment period, patients in the alogliptin group were given metformin and alogliptin, patients in the acarbose group were given metformin and acarbose and patients in the repaglinide group were given metformin and repaglinide. At week 0, 12 and 24 of the clinic trial, hemoglobin A1c(HbA1c), fasting plasma glucose(FPG), 2 h postprandial blood glucose(2 hPBG), triglycerides(TG), total cholesterol(TC) were measured, all hypoglycemic events and gastrointestinal reaction during the trial recorded and the percentage of patients achieving HbA1c target of <7% were recorded.
〖HTH〗〖WTHZ〗Results〖HTSS〗〓After the treatment, HbA1c, FPG and 2 hPBG in three groups lowered obviously. Comparing with those before treatment, the differences were significant(P＜001), while there were no significant changes among the three groups in TG and TC（P＞005）. There were no significant difference among the three groups in HbA1c, FPG, 2 hPBG , TG and TC（P＞005）. After the treatment, the percentage of patients achieving HbA1c target of <7% was highest(74.36%, χ2=6.496， P＜001), the incidence of hypoglycemia(2.56%， χ2=16.955， P＜001) and gastrointestinal reaction(0.00%, χ2=37.853， P＜001) in the alogliptin group was lowest among the three groups.
〖HTH〗〖WTHZ〗Conclusion〖HTSS〗〓The efficacy of alogliptin was not inferior to that of acarbose and regrainidein patients with type 2 diabetic mild cognitive impairment inadequately controlled by metformin, while compared with them, the incidences of hypoglycemia and gastrointestinal reaction were lowest in those treated by alogliptin.

Key words: diabetes mellitus, type 2, mild cognitive impairment, alogliptin

王〓静1，刘〓璠2*，董闪闪2，冯红云2，杨爱格2，周慧敏2. 2型糖尿病轻度认知功能障碍患者应用阿格列汀治疗的有效性及安全性[J]. 河北医科大学学报, doi: 10.3969/j.issn.10073205.2019.01.009.

WANG Jing1， LIU Fan2*, DONG Shanshan2, FENG Hongyun2, YANG Aige2, ZHOU Huimin2. Efficacy and safety of alogliptin for patients with type 2 diabetic mild cognitive impairment#br#[J]. Journal of Hebei Medical University, doi: 10.3969/j.issn.10073205.2019.01.009.

[1]	贺佳, 魏枫. 长链非编码RNA NEAT1在糖脂代谢相关疾病发展中的作用及机制研究进展 [J]. 河北医科大学学报, 2023, 44(9): 1103-1108.
[2]	李芳, 李志红, 姚明言, 尹飞. 能量代谢通路TNAP在2型糖尿病患者的表达及对脂肪细胞功能调控的机制研究 [J]. 河北医科大学学报, 2023, 44(8): 894-899.
[3]	邢玉微, 孙泽楠, 柴雪姣, 位庚. 外周血miR-92b-5p与miR-148b-3p在2型糖尿病进展至糖尿病肾病中的表达及交互作用 [J]. 河北医科大学学报, 2023, 44(6): 654-659.
[4]	张桐毓, 杨传慧, 徐宁. 糖尿病周围神经病变炎症因子变化及与神经传导速度相关性 [J]. 河北医科大学学报, 2023, 44(5): 517-520,571.
[5]	王文琦, 丁海霞, 张涛 . 度拉糖肽对2型糖尿病合并冠心病患者心肌缺血总负荷及内皮功能的影响 [J]. 河北医科大学学报, 2023, 44(5): 521-525.
[6]	尉全平, 杨建宝, 翟洪然, 侯凤香, 付晓康, 孙子梅. 孕妇糖代谢异常及维生素D缺乏对子代甲状腺功能的影响[J]. 河北医科大学学报, 2023, 44(5): 553-556,578.
[7]	田梅梅, 李敏, 刘岩, 徐静, 李玉坤, 支忠继. 2型糖尿病合并冠心病患者血浆半乳糖凝集素3水平及相关因素研究 [J]. 河北医科大学学报, 2023, 44(4): 402-406.
[8]	谷梁, 马小溪. 甲状腺激素水平与糖尿病肾病患者高尿酸血症发生的相关性 [J]. 河北医科大学学报, 2023, 44(4): 407-411.
[9]	鲁晓琪（综述）, 李淑娟（审校）. 糖尿病和牙周炎的骨代谢关系的研究进展 [J]. 河北医科大学学报, 2023, 44(4): 484-488.
[10]	李雪景, 陈冬梅, 段佳良, 姚一民, 尚庆丽. 联合手术治疗增殖性糖尿病视网膜病变的继发性闭角型新生血管性青光眼的临床效果观察 [J]. 河北医科大学学报, 2023, 44(3): 319-323.
[11]	杨洁, 丁文萃, 王海英, 史亚男. 甲状腺过氧化物酶抗体与2型糖尿病下肢血管病变的相关性研究 [J]. 河北医科大学学报, 2023, 44(2): 152-156.
[12]	廖苏丹, 张弛, 苏钢. 血清GLP-1、hs-CRP与2型糖尿病患者代谢综合征及认知功能的相关分析 [J]. 河北医科大学学报, 2023, 44(2): 157-160,183.
[13]	吴苏敏, 周欣, 王丽波. 血清CMKLR1、FSTL1水平与糖尿病视网膜病变严重程度相关性 [J]. 河北医科大学学报, 2023, 44(2): 189-193,213.
[14]	朱明明, 李宗虎, 郑宪玲, 王颖霞, 张树杰, 张瑞清. 不同骨密度水平的糖尿病患者外周血Omentin-1水平、脂代谢、氧化应激的表达及意义 [J]. 河北医科大学学报, 2023, 44(11): 1267-1273.
[15]	王臣廷, 吕翠君, 安向莲, 袁敏, 刘建凤. 2型糖尿病合并大血管病变与血浆NGAL表达、胫前色素沉着斑的相关性 [J]. 河北医科大学学报, 2023, 44(11): 1274-1278.

2型糖尿病轻度认知功能障碍患者应用阿格列汀治疗的有效性及安全性

Efficacy and safety of alogliptin for patients with type 2 diabetic mild cognitive impairment#br#

HTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价